USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets
Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets
RELEASE DATE
22-Oct-2004
22-Oct-2004
REGION
North America
North America
Research Code: F138-01-00-00-00
SKU: HC01415-NA-MR_05864
$2,450.00
In stock
SKU
HC01415-NA-MR_05864
Description
Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets is a very dynamic field undergoing many changes. This research service includes in depth analysis of the total market as well as the cytoxic and targeted therapy markets. This analysis includes patient forecasts, revenue forecasts, product/pipeline analysis and oncologist's perspectives on the new cancer fighting mechanisms.
Table of Contents
Executive Summary
- Executive Summary
Research Scope and Segmentation
- Scope and Segmentation
- Research Methodology
Disease Overview
- Introduction
- Etiology
- Diagnosis and Staging
- Treatment Overview
Patient Forecast
- Patient Incidence Forecast
- Patients per Line of Therapy
- Patient Forecast of Untreated Patients
Line of Therapy Revenue Forecasts
- Market Engineering Measurements
- Revenue Forecasts for First Line Therapy
- Revenue Forecasts for Second Line Therapy
- Revenue Forecasts for Third Line Therapy and Unmet Need Population
General Market Trends
- Industry Challenges
- Market Drivers
- Market Restraints
- Oncologists' Perspectives on Current and Future NSCLC Therapies
Frost & Sullivan Awards
- Customer Service Leadership Award
- Company of the Year Award
- Technology Innovation Award
- Product of the Year Award
Overview
Forecasts and Trends
Competitive Analysis
Overview
EGF Pathway
Angiogenesis
Cell Proliferation/Apoptosis Pathway
Immune Response Pathway
Competitive Analysis
Decision Support Database
Popular Topics
plastic waste management market
glucose monitoring devices market
Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets is a very dynamic field undergoing many changes. This research service includes in depth analysis of the total market as well as the cytoxic and targeted therapy markets. This analysis includes patient forecasts, revenue forecasts, product/pipeline analysis and oncologist's perspectives on the new cancer fighting mechanisms.
| No Index | Yes |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | F138-01-00-00-00 |
| Is Prebook | No |